Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane.
Marijke Linschoten, Jesse Geels, Erik van Werkhoven...
https://pubmed.ncbi.nlm.nih.gov/39875951/Actively Recruiting
Led by Stichting Hemato-Oncologie voor Volwassenen Nederland · Updated on 2026-09-23
324
Participants Needed
25
Research Sites
N/A
Total Duration
Researchers are investigating whether dexrazoxane can prevent heart damage caused by anthracycline chemotherapy in patients with diffuse large B-cell lymphoma DLBCL. This condition, known as anthracycline-induced cardiac dysfunction AICD, can lead to irreversible heart muscle damage and heart failure. Patients with DLBCL are at higher risk of AICD due to their treatment regimen and longer survival, making prevention of heart damage important. This is a national phase III randomized controlled trial conducted across multiple hospitals in the Netherlands. Participants will receive six cycles of R-CHOP21 chemotherapy, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. They will be randomly assigned to either receive dexrazoxane intravenously before doxorubicin infusion or to receive standard treatment without dexrazoxane. Some patients with double hit lymphoma may receive lenalidomide as part of their regimen. The trial does not use placebo due to the nature of dexrazoxane. Cardiac function will be monitored using echocardiography before treatment and at 4 and 12 months after treatment starts. Participants will undergo heart function tests, metabolic remission assessments, survival evaluations, blood biomarker tests, and quality of life questionnaires during the study. The main outcome is the occurrence of significant heart function decline within 12 months. The study will also assess whether dexrazoxane affects cancer treatment effectiveness. Participants will be followed for at least one year to monitor heart health and cancer status, with regular visits for evaluations and treatment administration.
CONDITIONS
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
A
A. van Rhenen, MD
M
M.P.M. Linschoten, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Stichting Hemato-Oncologie voor Volwassenen Nederland
Lead Sponsor
UMC Utrecht
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 18 weeks
Participants receive six cycles of R-CHOP21 chemotherapy with or without dexrazoxane before doxorubicin infusion, depending on random assignment.
6 treatment visits
Duration - 12 months post-treatment
Participants have heart function and cancer status monitored with echocardiograms and other assessments at 4 and 12 months after starting treatment.
2 follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Marijke Linschoten, Jesse Geels, Erik van Werkhoven...
https://pubmed.ncbi.nlm.nih.gov/39875951/Stichting Hemato-Oncologie voor Volwassenen Nederland
Lead Sponsor
UMC Utrecht
Collaborating Sponsor